This is a summary of the glycine and N-acetylcysteine amounts reported in published GlyNAC clinical trials — what scientists have tested, not a recommendation for any individual's use. Geroevidence does not provide dosing guidance; consult a licensed physician for any clinical decision.
This article reports what specific published trials tested in their study protocols. It is historical and descriptive — it does not constitute a dosing recommendation, clinical guidance, or treatment protocol. GlyNAC is not FDA-approved for any indication, and its components are sold as dietary supplements. Any use should be discussed with a licensed physician evaluating an individual's specific health profile.
The GlyNAC protocol studied in the two Baylor College of Medicine trials (Kumar et al., 2021 and its 2023 extension) supplied glycine and N-acetylcysteine dosed by body weight — approximately 1.33 mmol/kg/day of each — split across daily doses, for 16 to 24 weeks depending on the trial. A separate, larger 2022 multi-dose RCT (n=114, published in Frontiers in Aging) tested a range of fixed doses rather than weight-based dosing, to characterize a dose-response relationship for redox and oxidative-stress markers.
None of these trials tested glycine or NAC alone at these doses as a comparator arm against the combination — the trials were designed to test GlyNAC as a paired intervention, on the mechanistic premise that glycine and cysteine (from NAC) are both independently rate-limiting for glutathione synthesis. This is a meaningful distinction from the broader NAC-alone literature, which covers different indications (e.g., mucolytic use, acetaminophen overdose) at different doses entirely.
The 2021 Kumar trial included a 12-week washout period after the 24-week supplementation phase. Glutathione levels and downstream markers (oxidative stress, inflammatory cytokines, mitochondrial function) returned to pre-treatment baseline during this washout. No published trial has tested whether a shorter course, a lower maintenance dose, or intermittent dosing preserves any of the measured effects — the existing evidence describes continuous supplementation only.
No published trial has compared different GlyNAC doses against each other for longevity-relevant outcomes in a head-to-head design, established a minimum effective dose, or reported long-term (multi-year) safety data at these amounts. All three trials describing GlyNAC-specific benefit come from a small number of research groups; independent replication at other centers, with larger cohorts, is the clearest gap in the current evidence base.
Published trials describe what has been tested in a research context — they are not a substitute for individualized clinical judgment, and Geroevidence does not convert trial protocols into dosing recommendations for any reader. Anyone considering GlyNAC supplementation should discuss it directly with a licensed physician familiar with their full medical history.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.